{"organizations": [], "uuid": "165ea923d0e69b75ac5bd2ecff24cdee41e29e37", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-deinove-collaborates-with-naicons/brief-deinove-collaborates-with-naicons-on-antibiotics-project-idUSFWN1QQ0YA", "country": "US", "domain_rank": 408, "title": "BRIEF-Deinove Collaborates With Naicons On Antibiotics Project", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-03-08T19:49:00.000+02:00", "replies_count": 0, "uuid": "165ea923d0e69b75ac5bd2ecff24cdee41e29e37"}, "author": "", "url": "https://www.reuters.com/article/brief-deinove-collaborates-with-naicons/brief-deinove-collaborates-with-naicons-on-antibiotics-project-idUSFWN1QQ0YA", "ord_in_thread": 0, "title": "BRIEF-Deinove Collaborates With Naicons On Antibiotics Project", "locations": [], "entities": {"persons": [{"name": "deinove", "sentiment": "none"}], "locations": [{"name": "antibiot", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "gdynia newsroom", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 8, 2018 / 5:52 PM / Updated 10 minutes ago BRIEF-Deinove Collaborates With Naicons On Antibiotics Project Reuters Staff March 8 (Reuters) - DEINOVE SA: * COLLABORATES WITH NAICONS TO DISCOVER NEW ANTIBIOTICS IN THE FRAME OF THE AGIR PROJECT‍​ * AS 1ST STEP, WILL HAVE ACCESS TO 400 STRAINS CAREFULLY SELECTED FOR THEIR POTENTIAL * WILL USE ROBOTIC TECHNOLOGY PLATFORM TO DETECT AND CHARACTERIZE ANTIBIOTIC ACTIVITIES OF THESE STRAINS * IN CASE OF DISCOVERY OF STRAIN OF INTEREST, CO MAY ACQUIRE IT EITHER VIA COMMERCIAL LICENSE OR IN FULL OWNERSHIP * POTENTIAL ACQUISITION OF A STRAIN WOULD BE TO INITIATE DEVELOPMENT OF DRUG CANDIDATES Source text for Eikon: Further company coverage: (Gdynia Newsroom)", "external_links": [], "published": "2018-03-08T19:49:00.000+02:00", "crawled": "2018-03-08T20:06:11.010+02:00", "highlightTitle": ""}